Mar 06, 2023 / 12:30PM GMT
Operator
Good day, and thank you for standing by. Welcome to the BridgeBio Phase II Data Results for Infigratinib in Achondroplasia Event. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to Neil Kumar, Founder and CEO, BridgeBio.
Neil Kumar - BridgeBio Pharma, Inc. - Co-Founder, President, CEO & Director
Thanks, operator, and thanks, everyone, for taking the time to join us this morning. As a quick reminder, I'll be making forward-looking statements today, and please refer to our SEC documents for more information. We're collected to review our Phase II cohort 5 achondroplasia data, a data set that, as many of you will have read, accesses new heights in efficacy alongside a differentiated safety and convenience profile.
With these data, we answer key questions that have previously (inaudible) us, such as why have the responder rates reported across therapies to date been so low despite the consistency in specific FGFR3 point mutation in this condition? And why previously could
BridgeBio Pharma Inc PROPEL2 Update Transcript
Mar 06, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers